Vaccine Adjuvants Methods and Protocols
This collection seeks to elucidate the practical methods necessary for successful adjuvant development, with a particular focus on the synthesis, formulation, manufacturing, and characterization aspects involved. Beginning with an overview and a case stud
- PDF / 13,481,454 Bytes
- 373 Pages / 504.63 x 737.01 pts Page_size
- 96 Downloads / 157 Views
Christopher B. Fox Editor
Vaccine Adjuvants Methods and Protocols
METHODS
IN
MOLECULAR BIOLOGY
Series Editor John M. Walker School of Life and Medical Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK
For further volumes: http://www.springer.com/series/7651
Vaccine Adjuvants Methods and Protocols
Edited by
Christopher B. Fox Infectious Disease Research Institute, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA
Editor Christopher B. Fox Infectious Disease Research Institute Seattle, WA, USA Department of Global Health University of Washington Seattle, WA, USA
ISSN 1064-3745 ISSN 1940-6029 (electronic) Methods in Molecular Biology ISBN 978-1-4939-6443-7 ISBN 978-1-4939-6445-1 (eBook) DOI 10.1007/978-1-4939-6445-1 Library of Congress Control Number: 2016951959 © Springer Science+Business Media New York 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper This Humana Press imprint is published by Springer Nature The registered company is Springer Science+Business Media LLC New York
Preface “So far, the results have been very, very exciting…But now we got involved into practical application” --Edgar Ribi [1]
Vaccine adjuvants have an interesting and empirical history, which led immunologist Charles Janeway to refer to them as the “immunologist’s dirty little secret.” Nevertheless, pioneering work led by Edgar Ribi elucidated structure-function relationships of adjuvant components while emphasizing practical application and manufacturing aspects, leading to the development of the TLR4 ligand MPL® that is now contained in approved human vaccines. In recent years, progress in vaccine adjuvant technology has accelerated to an exciting pace, including FDA approval of adjuvant-containing vaccines such as Cervarix® (2009) and Fluad® (2015), and positive phase III clinical results of adjuvanted vaccines for malaria, shingles, and hepatitis B. In addition to these significant cli
Data Loading...
